Pharma companies are upping their U.K. social media marketing game with country-specific accounts

Social media
U.K.-specific social media marketing is on the rise by pharma companies.

Pharma social media guidelines in the U.S. are starkly different, and more open, than in other countries around the world. But that doesn’t mean pharma is simply sitting out social in other regions. In the U.K., for instance, more pharma companies are now adopting country-specific social media.

Novartis, for one, recently launched a U.K.-specific Twitter account , and other pharma companies are also beginning to follow suit, according to U.K.-based PMLiVE.

The market for social media "in terms of pharma in the U.K. is almost completely different from the U.S.,” which necessitates the need for separate country channels, Andrew Ross, media relations manager of The Association of the British Pharmaceutical Industry, told FiercePharma in an interview.

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

As in general advertising, product-specific brand mentions are banned in U.K. social media—except to healthcare professionals who have specifically agreed to receive messages. Still, that shouldn’t—and generally today, doesn’t—stop social media activity.

“There’s not anything stopping pharmaceutical companies from using social media in the U.K. provided it’s done in a responsible way and in line with the code of practice,” Ross said. “... Spending more money in the U.K. on social media output is definitely one of those things that need to be done because the benefit can be so big."

Disease awareness, community building, research and corporate news are all ways U.K.-based pharma social media can and are building local audience share. AstraZeneca and Bayer are two other big pharma companies that have specific U.K. Twitter accounts, but others including Pfizer have U.K.-specific social media accounts on YouTube and Facebook. In the U.K., Ross said people are on mainly on social media sites Twitter and LinkedIn, with fewer on Instagram and Facebook.

But do pharma companies need different Twitter handles in different countries? Yes, he said, because different relationships between pharma companies and their audiences—healthcare professionals and consumers— in different countries need tailored messaging to be relevant.

“As a U.K. consumer, looking at a corporate-run U.S. account or corporate-run account from somewhere like Japan, I’m not sure that would resonate with me near as well as something that was U.K.-led,” Ross said.

He also noted that with three-fourths of U.K. citizens using search engines for healthcare information online, not having a social media presence can lower a company’s search visibility.

Read more on

Suggested Articles

In a last-minute deal during North American trade talks, the Trump administration agreed to scrap rules protecting biologic drugs from copycat rivals.

Dupixent's number-one position in the eczema market will be tough to maintain as two dozen rivals line up to unseat it, Cantor Fitzgerald warns.

Just months after a C-suite shakeup at Amneal, the generics company has struck a $220 million deal for AvKare, known on the street as R&S Northeast.